Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Cortexin iconCortexinSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Cortexin

Beginner tier: 5 mg, daily · 2w on / 12w off · clinical trials

CognitiveResearch
~1-3 hours half-life (estimated)·Injection

Also known as: Cortexin, Кортексин (Russian)

A Russian multicenter, double-blind, placebo-controlled trial in 272 acute stroke patients reported benefit from adding Cortexin to standard therapy [1]. This bovine/porcine cerebral cortex extract contains standardized neuropeptides under 10 kDa, along with L-glycine, vitamins, and trace minerals. It's been approved in Russia since 1999 and prescribed across CIS countries for stroke, TBI, and cognitive decline. The catch: over 200 published studies exist, but almost all are Russian-language, and no FDA-equivalent approval exists anywhere outside the CIS region. Community users run 10-day IM courses 2 to 3 times per year for subtle, delayed-onset cognitive gains.

What Is Cortexin?

Over 200 published studies and 25+ years of clinical use across Russia and CIS countries. That's the evidence base behind Cortexin, a lyophilized polypeptide fraction extracted from the cerebral cortex of young cattle or pigs through acid extraction and purification at the Institute of Bioregulation and Gerontology in St. Petersburg.

The preparation belongs to the Khavinson peptide bioregulator class. Short-chain peptides under 10 kDa cross neuronal membranes and interact with chromatin, restoring expression of neurotrophic factors like BDNF and NGF. The result is a dual action: neuroprotection during acute injury plus longer-term neuroplasticity support through gene regulation.

Clinical applications span ischemic stroke, traumatic brain injury, chronic cerebrovascular insufficiency, and pediatric neurodevelopmental conditions. In acute ischemic stroke, a Russian multicenter placebo-controlled trial of 272 patients [1] found two 10-day courses worked best alongside standard therapy. In chronic cerebral ischemia, an RCT (n=189)[2] found dose-dependent benefits at 20 mg/day, and the authors reported good tolerability.

In the community, Cortexin occupies a quiet niche. Reddit mentions total roughly 20 to 40 threads. Users who try it consistently describe the same pattern: minimal subjective effects during the 10-day injection course, with cognitive clarity, improved memory consolidation, and mild anxiolytic quality emerging 1 to 4 weeks after the last injection. A meaningful minority reports zero effect. Access is the practical barrier; authentic GEROPHARM product requires cold-chain shipping from Russia. A 2022 Western meta-analysis [3] rated the overall evidence certainty as low to very low.

How Cortexin Works

Cortexin operates through multiple pathways because it's a polypeptide complex, not a single molecule. The primary mechanism centers on tissue-specific bioregulation at the genomic level. Short-chain peptides in the 1 to 10 kDa range cross cell membranes and interact with promoter regions of genes encoding BDNF and NGF. This upregulation of neurotrophin expression promotes neuronal survival, synaptic plasticity, and axonal regeneration.

At the receptor level, Cortexin shifts the balance between glutamatergic excitation and GABAergic inhibition. Under ischemic conditions, it reduces pathological glutamate release and attenuates NMDA receptor-mediated calcium influx. That limits excitotoxic neuronal death, the primary cause of irreversible damage during stroke. Electrophysiological studies confirm normalization of cortical bioelectrical activity and improved interhemispheric coherence on EEG.

Direct antioxidant properties round out the profile. Cortexin scavenges reactive oxygen species and boosts endogenous antioxidant enzymes including superoxide dismutase and glutathione peroxidase. Lipid peroxidation in neuronal membranes drops, preserving membrane integrity during oxidative stress. Additional downstream effects include stabilization of mitochondrial membrane potential, caspase-3 downregulation (reducing apoptotic signaling), and modulation of IL-1beta and TNF-alpha in injured tissue.

Cortexin Benefits

  • Cortexin benefits center on neuroprotection, neurological recovery, and delayed-onset cognitive improvement across clinical and community settings.
  • Stroke recovery support: a Russian multicenter, placebo-controlled trial in 272 acute stroke patients reported benefit from adding Cortexin to standard care [1]. Two 10-day courses worked best.
  • Dose-dependent recovery in chronic cerebral ischemia: 20 mg once daily IM beat 10 mg on neurological symptoms, fatigue and sleep. The multicenter RCT split 189 patients into 20 mg, 10 mg and basic-treatment groups [2].
  • Cognitive clarity and memory consolidation are the most consistently reported community benefits; effects emerge 1 to 4 weeks post-course and persist 6 to 10 weeks before fading.
  • EEG normalization and improved cortical bioelectrical activity documented in clinical studies, with better interhemispheric coherence tracked across treatment courses.
  • Pediatric use in children with speech delay, ADHD, or after-effects of perinatal brain injury. A Russian multicenter study treated 635 children aged 3 to 7 with one 10-injection course [4]. It compared scores before and after treatment, with no placebo group, and reported better attention, memory and thinking.
  • Reduced post-traumatic epilepsy risk following TBI, with improved Glasgow Outcome Scale scores at follow-up in traumatic brain injury studies.

Cortexin: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 8 key studies·Research only

Cortexin demonstrates consistent neurological benefit vs. placebo in Russian RCTs for ischemic stroke and TBI.

Dosing studied: 10 mg IM once daily × 10 days; 20 mg once daily IM tested in one RCT (PMID 30335070)
Read the evidence (key study, limitations)

Evidence base is large (200+ papers) but predominantly Russian-language with limited independent replication. Best evidence is in acute stroke (multicenter placebo-controlled trial, n=272)[1] and chronic cerebral ischemia (n=189)[2].

Key Study

PMID 24874316 (Aliferova et al. 2014): multicenter double-blind placebo-controlled trial of Cortexin in 272 patients with acute ischemic stroke; two 10-day courses gave the best therapeutic effect.

Limitations

Predominantly Russian-language literature; minimal independent Western replication; polypeptide complex (not single molecule) limits PK/PD characterization; evidence certainty rated low-to-very-low in the only Western meta-analysis (PMID 36324709).

Community Experience
Weak
3.2/5
Based on ~20–40 Reddit threads total (low volume)

Community rates Cortexin as a subtle, delayed-onset cognitive enhancer rather than an acute nootropic.

Community dosing: 10 mg IM once daily × 10 days; some users run 10 mg BID (20 mg/day)
Read the reports (what users report 4, common issues 5)

Responder rate is variable: a meaningful minority reports no effect. Most prized for post-TBI recovery and general neuroplasticity rather than performance optimization.

What users report (4)
  • Subtle but persistent cognitive clarity and memory consolidation (effects emerge 1–4 weeks post-course)
  • Mild anxiolytic effect without stimulation
  • Accelerated recovery reported in users with prior TBI or concussion history
  • Improved organizational thinking and word retrieval
Common issues (5)
  • Highly variable response: meaningful minority reports zero effect
  • Difficult sourcing and cold-chain reliability outside Russia/CIS
  • IM-only administration barrier for self-administration
  • Prion/animal-brain origin causes hesitancy in Western users
  • Cost-to-effect ratio questioned given uncertain efficacy
Partially Aligned

Science and community agree on 10 mg/day × 10-day IM course and delayed-onset timeline. Science focuses on neurological rehabilitation (stroke, TBI) while community uses it primarily for cognitive enhancement in healthy individuals: an extrapolation beyond the validated clinical population. Community confidence in effects is weaker than the clinical trial data would suggest.

Cortexin Dosage Guide

Clinical TrialRussian registered pharmaceutical: 10 mg IM daily for 10 days (stroke rehabilitation RCTs); 20 mg IM once daily for 10 days in one chronic cerebral ischemia RCT (PMID 30335070)
LevelDose / InjectionFrequency
Beginner5 mg
DailyTrack
Moderate10 mg
DailyTrack
Aggressive20 mg20 mg is two 10 mg vials (Fedin 2018 gave 20 mg IM once daily); split it across two injections.
DailyTrack
Note:

Cortexin ships as a lyophilized powder in 5 mg or 10 mg vials. You'll reconstitute each vial with 1 to 2 mL of sterile water for injection right before use. Don't store the reconstituted solution; use it immediately.

For a 10 mg vial reconstituted with 1 mL sterile water: you get 10 mg/mL concentration. Draw up 100 units (the full 1.0 mL) on a U100 insulin syringe for a 10 mg dose. For the 5 mg beginner dose from a 10 mg vial, draw 50 units (0.5 mL). For a 5 mg vial with 1 mL water, the full syringe is your dose.

The non-obvious thing most beginners miss: you won't feel much during the 10-day course. Peak effects show up 1 to 4 weeks after the last injection. Evaluating at Day 10 is the single most common mistake; give it a full month before judging.

If the injection hurts, switch your diluent from sterile water to 0.5% procaine solution (unless you have a local anesthetic allergy). Deep IM injection into deltoid or gluteal muscle, rotated daily, minimizes site reactions. Cold-chain matters; inspect the powder on arrival. It should be white to off-white. Discard if discolored, clumped, or if the vial seal is broken.

Cycling Protocol

On Period
2 weeks
Off Period
12 weeks

Standard Russian protocol: 10-day treatment course (daily IM injections), repeated 2-4 times per year with at least 3-month intervals between courses. Acute conditions may use two courses back-to-back with a 10-day break.

Calculate your Cortexin dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

Cortexin Protocols by Goal

beginnerClinical Trial10 days; repeat 2–4 times per year with minimum 3-month intervals
Standard 10-day course
Wk 2
10 mg · Once daily (morning) · Intramuscular (IM)

Expected: Measurable improvement in neurological deficit scores by Day 8–10; continued functional improvement for 4–8 weeks post-course as neurotrophic changes mature.

Monitor: No routine labs required. Observe for injection site reactions and allergic response (animal-derived product). In stroke/TBI patients, track neurological deficit scales (NIHSS, mRS) at Day 10 and 30-day follow-up.

How to Inject Cortexin

  1. 1
    Step 1

    Remove one Cortexin vial (10 mg) from refrigerator storage (2 to 8 degrees C). Allow to reach room temperature for 2 to 3 minutes. Inspect the lyophilized powder; it should be white to off-white with no discoloration or clumping.

  2. 2
    Step 2

    Using a 3 mL syringe with a drawing needle (18 to 21 gauge), draw 1 mL of sterile water for injection or 0.5% procaine solution. Inject the diluent slowly down the side of the vial. Gently swirl until fully dissolved. Do not shake.

  3. 3
    Swap to a 25 to 27 gauge intramuscular needle

    Draw the full 100 units (1.0 mL) from the vial. This equals your 10 mg dose. For a 5 mg dose from a 5 mg vial reconstituted with 1 mL, draw the full 100 units.

  4. 4
    Step 4

    Choose your injection site: deltoid (upper arm) or gluteal muscle (upper outer quadrant of the buttock). Clean the area with an alcohol swab.

  5. 5
    Insert the needle at a 90-degree angle into the muscle

    Inject slowly over 1 to 2 minutes. Slow injection reduces pain and improves absorption.

  6. 6
    Step 6

    Withdraw the needle, apply gentle pressure with a cotton pad. Rotate injection sites daily across the 10-day course.

  7. 7
    Inject every morning for 10 consecutive days

    Morning timing is preferred to avoid potential sleep disturbances. Repeat the 10-day course every 3 to 6 months.

  8. 8
    Discard any remaining reconstituted solution

    Do not store or reuse.

Pediatric dosing: children under 20 kg receive 0.5 mg/kg/day, not exceeding 10 mg total.

Mixing your own vial? Use the Cortexin reconstitution calculator for the exact diluent-to-dose math on any vial size.

Cortexin Stacking Protocols

Works With

Avoid

Other CNS-active peptides (simultaneous courses)

Additive neurostimulatory effects possible when stacking multiple neuropeptide complexes simultaneously. No formal interaction data exists. Running Cortexin and Cerebrolysin at the same time is common practice, but adding a third CNS-active peptide complex (e.g., Selank + Semax + Cortexin + Cerebrolysin all at once) increases monitoring complexity without validated safety data.

Procaine/novocaine diluent (in patients with local anesthetic allergy)

Cortexin is sometimes reconstituted with 0.5% procaine to reduce injection pain. Contraindicated in patients with known allergy to local anesthetics (procaine, lidocaine, amide-class). Use sterile water for injection as the safe default diluent.

Do not combine

Estimated Cost

Generic / Research
Overseas listings: ~$42 USD for 10-vial pack (10 mg/vial); stock intermittent
Compounded
Other international listings: $64–$138 USD for 10-vial pack depending on quantity tier.

Pricing updated 2026-04-09

Cortexin Side Effects

Prion-related concerns get the most attention from Western users, so start there. Cortexin is derived from bovine or porcine cerebral cortex tissue. The preparation's strict molecular weight cutoff (under 10 kDa) excludes prion-sized proteins, and no prion transmission cases have been documented in 25+ years of clinical use across millions of treatment courses in Russia and CIS countries. The risk is theoretical but not zero, and it's the primary hesitancy factor for users outside the CIS region.

Allergic reactions are the most clinically relevant safety concern. Because the preparation contains animal-derived proteins, hypersensitivity responses including local urticaria and skin rash have been reported, primarily in patients with known sensitivity to bovine or porcine proteins. Anaphylaxis is rare but possible. Individuals with severe allergy history to bovine or porcine proteins should not use Cortexin.

Injection site pain is common with IM administration. Reconstituting with 0.5% procaine (novocaine) solution instead of sterile water reduces this substantially, but procaine carries its own contraindication: patients with known allergy to local anesthetics (procaine, lidocaine, amide-class) must use sterile water only.

Psychomotor agitation and sleep disturbances occur during the first few days of some treatment courses. These are transient and self-resolving, typically clearing by Day 4 to 5. Moving the injection to morning administration prevents most sleep disruption.

Transient headache and dizziness shortly after administration are the most commonly noted side effects in clinical literature. Adverse event rates in RCTs were comparable to placebo.

Pregnancy and breastfeeding: insufficient safety data exists. This is a contraindication. Known hypersensitivity to Cortexin, glycine, or other excipients is also a hard stop.

When to stop: any sign of allergic reaction (rash, urticaria, facial swelling, respiratory distress). When to see a doctor: anaphylactic symptoms, persistent injection site infection, or psychomotor agitation that doesn't resolve after Day 3 to 4 of a course.

Common Issues & Solutions

No effect after first course: Cortexin effects are delayed: peak benefit emerges 1–4 weeks post-course, not during. Users who assess at Day 10 routinely miss the response window. Evaluate at 3–4 weeks post-course.

Injection site pain: Switch diluent from sterile water to 0.5% procaine solution (if no local anesthetic allergy). Ensure deep IM injection technique; superficial injection increases pain. Rotate sites each day.

Psychomotor agitation or sleep disruption (Days 1–3): Transient and well-documented. Move injection to morning if administering in the evening. Usually self-resolves by Day 4–5.

Vial received warm (cold-chain failure): Lyophilized powder requires 2–8°C storage. If received at room temperature for >24–48 hours, efficacy may be compromised. Verify the source uses a cold-chain guarantee with insulated packaging and ice packs.

Diminishing returns with repeated courses: Clinical data shows progressive improvement across courses in chronic conditions; in healthy users, benefit may plateau. If no additional benefit after 3–4 courses per year, consider spacing courses further apart or switching to a single annual course.

Ask AI about this page

Ask AI for a second opinion on Cortexin dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (insufficient safety data)
  • Known hypersensitivity to Cortexin or animal-derived brain peptides
  • Severe allergic history to bovine or porcine proteins
  • Active anaphylactic conditions
  • Individual intolerance to glycine or other excipients

Drug Interactions

  • No significant drug interactions have been reported in clinical literature
  • Compatible with standard stroke therapy including anticoagulants and antihypertensives
  • May be combined with Cerebrolysin though no formal interaction studies exist
  • Use caution with other CNS-active peptides: additive neurostimulatory effects possible
  • Procaine diluent should not be used in patients with known local anesthetic allergy

Product Quality

Recommended Monitoring

TestWhenTarget
Neurological deficit assessment (NIHSS, mRS, or MMSE)Baseline before course; Day 10; 30-day post-courseReduction in NIHSS score; improvement in mRS toward 0–2; MMSE improvement of ≥2 points in cognitive decline
Allergy/hypersensitivity observationAfter first injection and first 3 injections of any new batchNo injection site reaction beyond mild transient erythema
Neurological deficit assessment (NIHSS, mRS, or MMSE)

Primary efficacy endpoint in clinical trials. Tracks neurological improvement in stroke/TBI use case.

Allergy/hypersensitivity observation

Animal-derived protein complex with theoretical immunogenicity. Allergic reactions (urticaria, local rash) documented rarely.

Cortexin Before and After

Days 1-3

Minimal noticeable effects. Some patients report mild psychomotor activation or slight headache as the polypeptide complex begins to act.

Days 4-7

Gradual improvements in mental clarity, attention, and alertness. Stroke patients may begin showing measurable improvements on neurological deficit scales.

Days 8-10

Peak benefits of the treatment course. Improved cognitive function, better EEG patterns, and continued neurological recovery in stroke and TBI patients.

Weeks 2-8
post-course

Effects persist and may continue to improve after the injection course ends due to ongoing gene expression changes and neurotrophic factor upregulation.

3-6 months
repeat courses

Cumulative benefits with repeated treatment courses. Clinical studies show progressive improvement with each successive 10-day course over a 12-month period.

What to Expect

Days 1 to 3: Largely uneventful. The polypeptide complex begins interacting with neuronal gene promoters; BDNF and NGF upregulation starts at the molecular level, but nothing measurable happens yet. Some users report very mild alertness or a slight headache on Day 1 or 2. Injection site pain and transient dizziness are possible. Psychomotor agitation occurs in some users but typically self-resolves.

Days 4 to 7: Subtle shifts begin. Community users describe gradually improving mental clarity, better attention, and a sense of alertness that's hard to pin down. EEG bioelectrical activity begins normalizing in monitored patients. Nothing dramatic.

Days 8 to 10: The course ends here. Clinical studies show peak measurable changes on neurological deficit scales. BDNF and NGF upregulation reaches its maximum. But here's the counterintuitive part: most community users still don't feel a clear subjective difference at this point. That comes next.

Weeks 1 to 4 post-course: This is the real effect window. Neurotrophic factor changes continue expressing after the last injection. Synaptic plasticity and axonal regeneration keep building. Community users consistently report peak subjective effects during this phase: sharper memory consolidation, clearer thinking, and a mild anxiolytic quality. The effects are described as subtle but distinct from baseline.

Months 2 to 3 (inter-course interval): Benefits persist but gradually fade over 6 to 10 weeks. Clinical studies show progressive improvement with each successive course across a 12-month period. Most users schedule their next course around the 3-month mark, matching the established Russian clinical protocol.

Detailed Timeline: Science vs Community

Days 1–3
Science

Polypeptide complex begins interacting with neuronal gene promoters; BDNF/NGF upregulation initiates. No measurable functional changes at this stage.

Community

Largely uneventful. Some users report very mild alertness or slight headache on Day 1–2.

Days 4–7
Science

Gradual improvements in EEG bioelectrical activity and neurological deficit scores in clinical patients. BDNF/NGF levels rising. Antioxidant and anti-excitotoxic effects ongoing.

Community

Subtle improvements in mental clarity, attention, and alertness noted by responsive users. No dramatic effect.

Days 8–10
Science

Peak measurable changes on neurological deficit scales in RCTs. Normalization of cortical bioelectrical activity on EEG. Maximum BDNF/NGF upregulation achieved.

Community

Most users still not feeling a clear subjective effect at Day 10. Course ends here.

Weeks 1–4 (post-course)
Science

Neurotrophic factor changes continue to express after the injection course ends; synaptic plasticity and axonal regeneration processes ongoing. Functional recovery continues in clinical patients.

Community

Most users report peak subjective effects here: memory consolidation, cognitive clarity, mild anxiolytic quality. Effects described as subtle but distinct from baseline.

Months 2–3 (inter-course interval)
Science

Persistent but gradually fading neurotrophic benefit. Clinical studies show progressive improvement with each successive course over a 12-month period.

Community

Effects fade gradually over 6–10 weeks post-course. Most users schedule the next course at 3 months.

Pharmacokinetics

Half-Life
2h
Bioavailability
IM: assumed high for low-molecular-weight peptide fractions
Tmax
~30-60 minutes (estimated)
Data Confidence
low

Source: Estimated from polypeptide fraction kinetics; individual component PK not fully characterized (Skoromets et al., 2018)

Pharmacokinetics: Active Dose Over Time

t½ = ~1-3 hours (estimated, polypeptide complex)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Cortexin

  • Post-ischemic stroke patients in recovery phase
  • Traumatic brain injury patients
  • Adults with age-related cognitive decline
  • Children with perinatal brain injury or neurodevelopmental delays
  • Patients with chronic cerebrovascular insufficiency
  • Individuals recovering from neurosurgical procedures

Related Peptides

What Changed for Cortexin

  1. Dosing

    Corrected Oct 20, 2026: cortexin's aggressive tier is 20 mg once daily, the arm Fedin 2018 gave, not 10 mg twice daily, per the full text (PMID 30335070).

    Before: Aggressive 10 mg twice daily, noted: the trial gave 20 mg as one IM injection once daily After: Aggressive 20 mg once daily, the Fedin 2018 trial arm (PMID 30335070), noted: 20 mg is two 10 mg vials

    What this does not mean: The daily total is unchanged. The trial gave 20 mg IM once daily for 10 days to 69 adults aged 50 to 80 with chronic cerebral ischemia. No trial tested healthy adults or a twice-daily split.

    Source: Zh Nevrol Psikhiatr Im S S Korsakova 2018, Dose-dependent effects of cortexin in chronic cerebral ischemia (Fedin et al., PMID 30335070), full text on the publisher page: 69 patients got 20 mg IM once daily (opens in a new tab) · Archived snapshot (opens in a new tab)

  2. Dosing

    Oct 18, 2026: cortexin's 10 mg twice-daily tier now notes that Fedin 2018 gave its 20 mg a day as one IM injection, per the full text (PMID 30335070).

    Before: Aggressive 10 mg twice daily with no note After: Aggressive 10 mg twice daily, noted: the trial gave 20 mg as one IM injection once daily; no trial tested 10 mg twice daily

    What this does not mean: The tier did not change. Its daily total matches the trial arm; only the split differs, and no trial tested it.

    Source: Zh Nevrol Psikhiatr Im S S Korsakova 2018, Dose-dependent effects of cortexin in chronic cerebral ischemia (Fedin et al., PMID 30335070), full text on the publisher page: 69 patients got 20 mg IM once daily (opens in a new tab) · Archived snapshot (opens in a new tab)

Peptide Schedule Research TeamReviewed Apr 7, 20268 Citations

References

  1. [1]Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke (Aliferova et al., Zh Nevrol Psikhiatr Im S S Korsakova 2014) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Dose-dependent effects of cortexin in chronic cerebral ischemia: results of a multicenter randomized controlled study (Fedin et al., Zh Nevrol Psikhiatr 2018) (opens in a new tab)(n=189)PubMed (opens in a new tab)PubMed
  3. [3]The efficacy and safety of animal-derived nootropics in cognitive disorders: Systematic review and meta-analysis (Cereb Circ Cogn Behav 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Results of a multicenter study on the efficacy of cortexin in treatment of cognitive dysfunction in children (Zykov et al., Zh Nevrol Psikhiatr Im S S Korsakova 2018) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 3 years at 2-8°C in original packaging, protected from light
After Reconstitution
Use immediately after reconstitution; do not store reconstituted solution
Temperature
2-8°C (36-46°F)

Frequently Asked Questions

Both are animal-brain polypeptide extracts used in Russian neurology, but Cerebrolysin is derived from porcine brain tissue broadly while Cortexin is extracted specifically from the cerebral cortex with a stricter <10 kDa molecular weight cutoff. Cerebrolysin has slightly more Western clinical trial data, including some independent European studies. Both are IM-only with similar 10-day course structures.

Yes. The lyophilized powder is stored at 2–8°C for up to 3 years in original packaging. Once reconstituted with sterile water or 0.5% procaine solution, it must be used immediately. No storage of reconstituted solution is recommended.

Many users report minimal subjective effects during the course itself, with effects emerging in the 1–4 weeks post-course as neurotrophic changes accumulate. This is the established pattern: Days 1–7 are largely symptom-free, with peak effects at Day 8–10 and post-course continuation.

Yes, in one multicenter RCT (Fedin 2018, PMID 30335070). It split 189 adults with chronic cerebral ischemia into three groups: 69 got 20 mg IM once daily, 68 got 10 mg once daily, and 52 got basic treatment only. Courses ran 10 days and repeated after 6 months. The 20 mg group improved more on neurological symptoms, fatigue and sleep, and the authors reported good tolerability. The aggressive tier follows that schedule, 20 mg once daily; the trial did not test 10 mg twice daily or enroll healthy adults.

Theoretical, but Cortexin's strict <10 kDa molecular weight cutoff means prion proteins (which are much larger) are excluded from the preparation. No prion transmission cases have been documented from Cortexin in 25+ years of use across millions of treatment courses in Russia and CIS countries.